Videos

Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.

The panelist discusses how asymptomatic sexually transmitted infections (STIs) can silently impact overall health, emphasizing the importance of comprehensive screening and education, particularly for less known STIs like trichomoniasis and Mycoplasma genitalium, while exploring how newer testing methods like nucleic acid amplification testing (NAAT) can address challenges in traditional screening access and improve patient care.

Panelists discuss alternative therapies for women who are not candidates for or choose not to use hormonal therapy, review nonhormonal treatment options recommended by the North American Menopause Society, and explore the growing importance of Level I evidence and consensus opinions in creating a more holistic view of available therapies, both hormonal and nonhormonal.

Panelists discuss why elinzanetant is likely to be associated with a lower risk of liver injury due to its distinct molecular structure compared to fezolinetant, and compare the adverse event profiles of the 2 drugs, highlighting that elinzanetant is more commonly associated with headache and fatigue while fezolinetant is linked to abdominal pain, diarrhea, insomnia, and back pain.

Panelists discuss why a warning about serious liver injury was added to the prescribing information for fezolinetant following a postmarketing case of drug-induced liver injury, and review updated guidelines for baseline liver testing, recommended monitoring, symptoms indicating the need to discontinue the medication, and key points for addressing patient concerns about liver health.